71 – 80 of 103
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Sentinel Node Procedure in Prostate Cancer : A Systematic Review to Assess Diagnostic Accuracy
(
- Contribution to journal › Scientific review
-
Mark
Reply to Glen D. Santok and Koon H. Rha' Letter to the Editor re : Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.0
(
- Contribution to journal › Letter
-
Mark
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
(
- Contribution to journal › Article
-
Mark
Familial Associations Between Prostate Cancer and Other Cancers
(
- Contribution to journal › Article
-
Mark
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer : A Semiecologic, Nationwide, Population-based Study
(
- Contribution to journal › Article
-
Mark
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
(
- Contribution to journal › Article
-
Mark
Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
(
- Contribution to journal › Article
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
(
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial